Category - Markets

Markets

HCW starts Arbutus Biopharma at buy; PT $10

H.C. Wainwright launched coverage of Arbutus Biopharma (NASDAQ:ABUS) with a “buy” rating and price target of $10. The stock closed at $4.41 on Dec. 16. Arbutus is primarily focused on discovering, developing and...

December 17, 2020

Markets

Maxim starts Cyclo Therapeutics at buy; PT $12

Maxim Group initiated coverage of Cyclo Therapeutics (NASDAQ:CYTH) with a “buy” rating and $12 price target. The stock closed at $3.85 on Dec. 16. Cyclo is developing a Phase 3-ready hydroxypropyl beta cyclodextrin...

December 17, 2020

Markets

Chardan starts CohBar at buy; PT $3

Chardan Research launched coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and price target of $3. The stock closed at $1.29 on Dec. 16. “We expect that Cohbar’s unique pipeline of mitochondrial derived...

December 17, 2020

Markets

Brookline starts X4 Pharma at buy; PT $21

Brookline Capital Markets launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $21 price target. The stock closed at $6.10 on Dec. 16. X4 Pharmaceuticals is focused on diseases resulting from...

December 17, 2020

Markets

Leede Jones Gable starts IntelGenx at speculative buy; PT $1 (Canadian)

Leede Jones Gable initiated coverage of IntelGenx Technologies (TSXV:IGX) with a “speculative buy” rating and price target of $1.00 (Canadian). The stock closed at 37 cents on Dec. 15. IntelGenx is a thin-film...

December 16, 2020

Markets

Leede Jones Gable starts IMV at speculative buy; PT $10.50 (Canadian)

Leede Jones Gable launched coverage of IMV (TSX:IMV) with a “speculative buy” and price target of $10.50 (Canadian). The stock closed at $4.03 on Dec. 15. IMV’s flagship technology platform is the lipid-based water-free...

December 16, 2020

Markets

Leede Jones Gable starts Liminal BioSciences at hold; PT $4

Leede Jones Gable initiated coverage of Liminal BioSciences (NASDAQ:LMNL) with a “hold” rating and $4 price target. The stock closed at $4.20 on Dec. 15. Liminal is a plasma products and anti-fibrotic small molecule...

December 16, 2020

Markets

Leede Jones Gable starts Oncolytics Biotech at speculative buy; PT $8.50 (Canadian)

Leede Jones Gable launched coverage of Oncolytics Biotech (TSX:ONC) with a “speculative buy” rating and $8.50 (Canadian) price target. The stock closed at $3.07 on Dec. 15. Oncolytics is a cancer-focused virus-based...

December 16, 2020

Markets

Leede Jones Gable starts Medical Facilities at buy; PT $10.50 (Canadian)

Leede Jones Gable initiated coverage of Medical Facilities (TSX:DR) with a “buy” rating and price target of $10.50 (Canadian). The stock closed at $7.32 on Dec. 15. Medical Facilities owns a majority stake in several U...

December 16, 2020

Markets

Leede Jones Gable starts CareRx at buy; PT $6.50 (Canadian)

Leede Jones Gable initiated coverage of CareRx (TSX:CRRX) with a “buy” rating and one-year price target of $6.50 (Canadian). The stock was quoted at $3.75, up 26 cents, near mid-day on Dec. 15. CareRx, formerly known as...

December 15, 2020

Category - Markets

Subscribe